Abstract
BACKGROUND: Primary liver cancer, particularly hepatocellular carcinoma (HCC), poses significant clinical challenges due to late-stage diagnosis, tumor heterogeneity, and rapidly evolving therapeutic strategies. While systematic reviews and meta-analyses are essential for updating clinical guidelines, their labor-intensive nature limits timely evidence synthesis. OBJECTIVE: This study proposes an automated literature screening workflow powered by large language models (LLMs) to accelerate evidence synthesis for HCC treatment guidelines. METHODS: We developed a tripartite LLM framework integrating Doubao-1.5-pro-32k, Deepseek-v3, and DeepSeek-R1-Distill-Qwen-7B to simulate collaborative decision-making for study inclusion and exclusion. The system was evaluated across 9 reconstructed datasets derived from published HCC meta-analyses, with performance assessed using accuracy, agreement metrics (κ and prevalence-adjusted bias-adjusted κ), recall, precision, F(1)-scores, and computational efficiency parameters (processing time and cost). RESULTS: The framework demonstrated good performance, with a weighted accuracy of 0.96 and substantial agreement (prevalence-adjusted bias-adjusted κ=0.91), achieving high weighted recall (0.90) but modest weighted precision (0.15) and F(1)-scores (0.22). Computational efficiency varied across datasets (processing time: 248-5850 s; cost: US $0.14-$3.68 per dataset). CONCLUSIONS: This LLM-driven approach shows promise for accelerating evidence synthesis in HCC care by reducing screening time while maintaining methodological rigor. Key limitations related to clinical context sensitivity and error propagation highlight the need for reinforcement learning integration and domain-specific fine-tuning. LLM agent architectures with reinforcement learning offer a practical path for streamlining guideline updates, though further optimization is needed to improve specialization and reliability in complex clinical settings.